logo-loader

NetScientific portfolio company ProAxsis sees direct sales of ProteaseTag® Active increasing by a factor of three in the second half

Published: 07:45 21 Nov 2017 GMT

Intellectual property
NetScientific holds a 57% stake in ProAxsis on a fully diluted basis

NetScientific PLC (LON:NSCI) has announced that its portfolio company, ProAxsis has revealed that direct sales of its ProteaseTag® Active Neutrophil Elastase Immunoassay (NEIA) will increase by a factor of three in the second half of 2017 compared to the first half.

The AIM-listed transatlantic healthcare IP commercialisation group added that ProAxsis also expects total revenue to surpass £1mln in 2018.

READ: Netscientific associate Vortex Biosciences makes first commercial sale

Commenting on the news, Francois Martelet, chief executive officer of NetScientific and chairman of ProAxsis, said: "We are pleased to see signs of rapid market adoption of the CE marked NEIA test which uses ProAxsis' market leading ProteaseTag® technology.

“We are especially encouraged to see the acceleration of sales through a combination of repeat orders and new customers from leading research institutions across Europe and the US.”

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

He added: “We expect 2018 to be a pivotal year for ProAxsis with further planned product launches and potential industry partnerships as value inflection points."

NetScientific holds a 57% stake in ProAxsis on a fully diluted basis.

NetScientific: Significant Advancement with Strategic Goals

  NetScientific PLC (AIM:NSCI) CEO Dr Ilian Iliev discusses the substantial progress made in achieving its strategic objectives for 2023, despite facing challenging market conditions. Iliev told Proactive's Stephen Gunnion the company, a listed deep tech investor, has capitalized on the...

1 week, 2 days ago